ALNY vs. ELAN: Alnylam Pharmaceuticals vs. Elanco Animal Health Stock Comparison

Company Profile

Alnylam Pharmaceuticals (ALNY) and Elanco Animal Health (ELAN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while ELAN is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Elanco Animal Health (ELAN) has an aggressive beta of 1.65, indicating higher sensitivity to broad-market moves, while Alnylam Pharmaceuticals (ALNY) is defensive at 0.45 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Alnylam Pharmaceuticals (ALNY) earns 138.07% on shareholders’ equity, ranked against its industry; Elanco Animal Health (ELAN) has no ROE this period.

Elanco Animal Health (ELAN) reports a negative net margin of -2.86%, usually indicating a net loss over the period. Meanwhile Alnylam Pharmaceuticals (ALNY) reports 52.85%, ranking against industry peers normally.

Alnylam Pharmaceuticals (ALNY) at 23.72% operates in the top operating margin quartile, ahead of Elanco Animal Health (ELAN) at 6.64%, which runs around its industry’s norm.

Profitability Metrics

Growth

Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Elanco Animal Health (ELAN) at 6.22% is closer to the peer norm — faster top-line expansion for ALNY.

Only one side can be read here: Elanco Animal Health (ELAN) reports EPS growth of -169.12%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Alnylam Pharmaceuticals (ALNY) shows current ratio of 2.48 against its industry benchmark, while Elanco Animal Health (ELAN) has no reading this period.

Elanco Animal Health (ELAN) at 0.64 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither Alnylam Pharmaceuticals (ALNY) nor Elanco Animal Health (ELAN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Alnylam Pharmaceuticals (ALNY) nor Elanco Animal Health (ELAN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Alnylam Pharmaceuticals (ALNY) trades at 7.88 times trailing earnings, ranked against its peers, while Elanco Animal Health (ELAN) has no P/E ratio this period.

Elanco Animal Health (ELAN) at 2.50 sits in the cheaper P/S ratio quartile while Alnylam Pharmaceuticals (ALNY) at 4.17 prices around its industry’s middle — ELAN costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Alnylam Pharmaceuticals (ALNY) at 5.79 and Elanco Animal Health (ELAN) at 1.95 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics